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Abstract
Objectives Summarize hepatitis C virus (HCV) prevalence
in injecting (IDU) and non-injecting drug users (NIDU), men
who have sex with men (MSM), sex workers, and prison
inmates in Latin America and the Caribbean (LAC).
Methods Systematic review on HCV prevalence in sub-
populations in LAC. Databases searched from 1-1-2000 to
10-30-2013. Inclusion criteria: prevalence studies in sub-
populations in LAC. HCV-antibody was marker for
prevalence of current/past HCV infection and HCV-RNA
for prevalence of HCV current infection.
Results IDU HCV current/past infection presented high-
est prevalence, from 1.7 % in Colombia to over 95 % in
Ciudad Juarez and Tijuana, Mexico and pooled regional
anti-HCV prevalence was 49 % (CI 95 % 22.6–76.3 %).
NIDU, MSM and sex workers anti-HCV prevalence was
below 10 %, and pooled regional prevalence of 4 % (CI
95 % 2.6–4.5 %), 3 % (CI 95 % 1.7–4.5 %) and 2 % (CI
95 % 1.0–3.4 %), respectively. Prison inmates presented
higher values, but prevalence decreased over the 15-year
time span (p\ 0.001). Current HCV infection from three
countries showed prevalence under 10 % in prison inmates
and 1–46 % among drug users.
Conclusions Disease burden is high and surveillance,
prevention and treatment should target these groups in
LAC.
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Abbreviations
LAC Latin America and the Caribbean
IDU Injecting drug users
NIDU Non-injecting drug users
MSM Men who have sex with men
HCV Hepatitis C virus
DU Drug users
Introduction
Hepatitis C virus (HCV) infection is a leading cause of
chronic liver disease, cirrhosis and hepatocellular carci-
noma (Perz et al. 2006). Hepatitis C causes chronic
infection in almost 3 % of the world population and, since
its discovery in 1989, has emerged as a worldwide public
health concern (WHO 2010). Recent estimates for Central,
South America and the Caribbean indicate HCV population
prevalence levels between 1.5 and 3.5 % (Mohd Hanafiah
et al. 2013). Furthermore, Brazil and Mexico together may
have 4 million people with HCV (Szabo et al. 2012). The
burden of HCV varies geographically and among subpop-
ulations (Szabo et al. 2012; Kershenobich et al. 2011;
Lavanchy 2011). Several studies from Latin America and
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the Caribbean (LAC) have reported a high prevalence
among injecting drug users (Weissenbacher et al. 2003)
and prison inmates (Guimaraes et al. 2001) as well as in
other vulnerable populations, such as sex workers (Pando
et al. 2006a, b), and men who have sex with men (MSM)
(Pando et al. 2012). No systematic review has been con-
ducted on HCV infection prevalence among specific
population groups in LAC. To effectively respond to viral
hepatitis C through provision of appropriate treatment and
care services, it is critical to document a disproportionate
impact and burden of disease among different population
groups in LAC. This study aims to summarize available
information on prevalence of hepatitis C infection in drug
users, injecting and non-injecting, MSM, sex workers, male
to female transgender populations and prison inmates in
LAC.
Methods
A systematic review and meta-analysis on hepatitis C
prevalence in different population groups in LAC was
conducted according to the PRISMA statement (Preferred
Reporting Items for Systematic Reviews and Meta-Anal-
yses) (Moher et al. 2009). Search terms (all fields) for the
PubMed, LILACS and SciELO databases were: ‘‘hepatitis
OR HAV OR HBV OR HCV OR HDV OR HEV’’ and
‘‘prevalence OR epidemiology’’ and, for the PubMed
search only, a combination of the names of regions,
countries and big cities in LAC (Electronic Supplemental
Material, Table 1 presents the search terms used for the
review). Searches included original articles in English,
Spanish, French or Portuguese. We also screened the ref-
erences of retrieved articles. One reviewer screened all
abstracts and full texts for the inclusion criteria and con-
ducted the data extraction. A second expert conducted data
extraction on a random sample of studies.
The inclusion criteria consisted of the following: pri-
mary sources published between 01/01/2000 and 10/01/
2013 with data on Hepatitis C prevalence in one or more of
the following populations from LAC countries: Sex
workers, MSM, transgender populations, prison inmates
and drug users. We defined key populations as both most-
at-risk populations and vulnerable populations according to
the 2013 WHO classification for HIV (WHO 2013a, b). If
several publications were based on the same study, only
one of the publications was included. Exclusion criteria
were studies with a sample size\75 and studies that did
not mention the testing markers. The sample size cutoff
criteria (75 participants or greater) were decided given the
paucity of studies in the region.
The flow chart of the systematic review and meta-
analysis is shown in Fig. 1.
Positivity to anti-HCV antibody was interpreted as current
and/or past infection (current/past). HCV-RNA positivity
was categorized as current infection. For HCV-RNA,
prevalence was given as percentage of the whole study
sample although testing was sometimes only done among
anti-HCV positive individuals. Whenever possible, preva-
lence from confirmatory tests was used. Wilson confidence
intervals were calculated for each prevalence point.
The quality of the included studies in the review was
evaluated with the QATSO scale developed by Wong et
col. (Wong et al. 2008). Two additional criteria were
evaluated: the acceptability of the case definition for each
subpopulation and for the outcome variable and the ade-
quacy of the sample size.
Data extraction
HCV prevalence was extracted from the studies based on
hepatitis C marker (antibody or RNA) and by population
group. Multiple center studies were split up into sites/cities
when possible. Therefore, one reference could yield mul-
tiple records. Additional characteristics collected were
gender, age group, genotype, data collection period, study
setting, country and city or area, sample size, and type of
laboratory test.
Statistical analysis
Linear and multiple regression analysis evaluated the influ-
ence of year of field work on prevalence, using R statistical
language and environment (R Core Team 2011). The anal-
ysis was applied within population groups if at least 5 data
points were available. For country, dummy variables were
created. The country having (1) the lowest prevalence and (2)
more than one data point was selected as reference.
Meta-analysis was performed using STATA 12 Soft-
ware Version 12.0. Prevalence was reported by 95 %
confidence intervals (CIs). Random effects models were
used, taking into account the possibility of heterogeneity
between studies, which was tested with the Cochrane Q test
and I2 test. We calculated prediction intervals (PI) to
evaluate the dispersion of the estimated prevalence’s.
Subgroup analyses were conducted for results controlling
(either by standardization or statistical adjustments) for risk
group of infection and country. We performed analyses
stratified by geographic area and year of field work.
Results
A total of 3400 references were identified in the three
databases (Fig. 1). Most of them were excluded after
revising the abstracts. Fifty-three full text citations were
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included. Only seven studies from the LILACS and one
from the SciELO database were included as most of the
citations were already found in PubMed. Fifty five studies
were excluded; seven due to small sample size, five among
drug users, one among prison inmates and one among
MSM, from Brazil, Puerto Rico and Mexico. Prevalence
was in range with included studies.
Seventy-five data points from the following countries
were available for current/past HCV infection: Argentina,
Brazil, Colombia, Dominican Republic, Mexico, Panama,
Peru, Puerto Rico, Uruguay and Venezuela. For current
HCV infection, based on HCV-RNA, 11 data points from
the following countries were included: Brazil, Mexico, and
Venezuela. The baseline characteristics of the studies
appear in Electronic Supplemental Material, Table 2.
All data for transgender populations were from studies
focusing on sex workers or conflating transgender and
MSM. Therefore, the transgender population was not
investigated separately.
Quality of studies
Results of the study quality assessment are provided in
Electronic Supplemental Material, Table 3. Eighty-eight






289 from Non- LAC countries
2055 without outcome of interest 
(Hepatitis C prevalence in groups of interest)
55 full texts excluded
7 Sample size < 75
14 Data duplication
19 No prevalence
14 without new data (reviews)
1 other population group
76 records included in database
Drug Users: 40 (39 for current/past HCV and 6 for current HCV) 
MSM: 7 (7 for current/past HCV and 0 for current HCV)
Prisoners: 14 (14 for current/past HCV and 5 for current HCV)
Sex Workers: 15 (15 for current/past HCV and 0 for current HCV)
Transgender: 6
(numbers do not add up due to duplications)




2 tracked from reviews
2452 titles and abstracts screened
108 full texts screened
Fig. 1 Flow diagram of the
study selection procedure for
the review on prevalence of
current and/or past Hepatitis C
infection in Latin America and
the Caribbean from 2000 to
2013
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percent of studies reported sampling methods, most of
them using non-probability sampling (70 %). Measure-
ment of HCV was by laboratory testing for all studies.
Thirteen studies had samples sizes of 100 or less and the
median sample size of those with sample size [100 was
270 (interquartile range Q25–Q75: 197–500). All the
studies used serological markers to diagnose hepatitis C
infection and the testing assays were specified in 96 % of
the studies. In the majority of cases, a single enzyme
immunoassay was used. Confirmatory or supplementary
testing was done by immunoblot assays in 20 % of
records.
Sex workers
Eight studies met the inclusion criteria, leading to 15 data
points on past/current HCV prevalence (Fig. 2) and no data
on current HCV infection prevalence.
Most of the studies focused on female sex workers in
five countries. The minimum age of participants was
18 years old, with average age around 27–29 years old in 8
studies, and three studies had average age of 33–36 years
old. Current/past infection rate of HCV was below 2 % in
Panama (Hakre et al. 2013), Peru (Valdivia et al. 2003;
Guerra Amaya et al. 2007) and Venezuela (Camejo and
Dı´az 2003), and was 0 % in three locations (Chiriquı´ and
Colo´n in Panama, and Lima, Peru). Highest values were in
Argentina (Salta) and Brazil (Southern region of Santa
Catarina State) with values up to 9 % (the latter study
included 9 % male sex workers and 56 % of the sample
inhaled illicit drugs). The pooled weighted estimate for
current/past HCV infection among sex workers in Latin
America based on available studies was 2 % (CI 95 %
1.0–3.4 %) with significant heterogeneity (p = 0.00) PI
(0.56, 5.32).
Among transgender sex workers, current/past HCV
prevalence was available from two studies with fig-
ures similar to those from studies among female sex
workers in Argentina and counting among the higher
results found in the region (7 % in Montevideo, and 5 % in
seven cities in Argentina) (Dos Ramos Farias et al. 2011;
Russi et al. 2003). The latter study also provided HCV
prevalence for male sex workers (current/past HCV
prevalence of 6 %).
Men who have sex with men
Seven data points from Argentina and Dominican Republic
were analyzed (Fig. 2). Two studies reported an average
participant age of 30 years old and in four study sites the
majority of participants (54–68 %) were \24 years old
(Johnston et al. 2013). No studies used HCV-RNA assays,
thus no data were available for current HCV infection.
Three studies from Buenos Aires seem to support an
increase in HCV prevalence between 2001–2003 and 2009
(Pando et al. 2006a, b, 2012; Segura et al. 2010). The
pooled estimate value for current/past HCV prevalence was
3 % (CI 95 % 1.7–4.5 %) with statistically significant
heterogeneity, PI (-1.12, 8.23).
Prison inmates
Thirteen studies from Brazil, Venezuela (Monsalve-Cas-
tillo et al. 2009) and Mexico (Alvarado-Esquivel et al.
2005) provided 14 data points for analysis; the majority of
studies were from Brazil (Fig. 2).
Multiple regression analysis indicated that anti-HCV
prevalence in prisons has gone down within 15 years
(p value 0.001). In Brazil, the oldest study from Sao
Paulo with 18.6 % of inmates reporting previous intra-
venous drug use had an extremely high prevalence of
41 % (Guimaraes et al. 2001). The most recent study was
from 2011 (Santa Cruz do Sul) and gave a prevalence of
10 % for anti-HCV (Rosa et al. 2012). In the 2004 study
in a prison in Goia, HCV prevalence was 15 %, but
increased to 21 % among drug users (Gonc¸alves 2005).
Pooled prevalence for current/past HCV among inmate
population was 12.5 % (CI 95 % 7.7–17.3 %) but
heterogeneity was statistically significant (p\ 0.000), PI
(10.67, 19.51).
HCV-RNA indicating current HCV infection was
analyzed in all three countries. In Brazil, prevalence was
stable at around 3 % in three different studies (Santos
et al. 2011; Barros et al. 2013; Pompilio et al. 2011).
Prevalence in Venezuela (Monsalve-Castillo et al. 2009)
was significantly lower than in Brazil. All except one
study evaluated genotypes. Taken these studies together,
genotypes were determined in 50 individuals, of which
90 % had genotype 1, being 1a the most common. 8 %
had genotype 3.
In three of the five studies, more than 80 % of the anti-
HCV positive cases were also HCV-RNA positive. Nev-
ertheless, two studies from Brazil presented a much higher
percentage of past infection (Barros et al. 2013; Pompilio
et al. 2011).
No significant difference in HCV prevalence was seen
by sex in the multiple regression analysis.
Drug users
Eight countries presented data on hepatitis C prevalence in
drug users (DU) resulting in 39 data points (Fig. 2), some
cFig. 2 Forest plot for hepatitis C infection prevalence in Latin
America and the Caribbean from 2000 to 2013. DU drug users, IDU
injecting drug users, NI DU non-injecting drug users, MSM men who
have sex with men
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distinguishing between injecting (IDU) and non-injecting
drug users (NIDU) (Ferreira et al. 2009; Bastos et al. 2000;
Campollo et al. 2012; Germano et al. 2010; Lopes et al.
2009; Muzzio 2010; Novais et al. 2009; Nunes et al. 2007;
Osimani 2003; Pereira et al. 2013; Rossi et al. 2008; Santos
Cruz et al. 2013).
Prevalence for anti-HCV in DU remained below 7 % in
the majority of studies. However, infection rates for cur-
rent/past HCV infection among DU were up to 67 % in
Argentina in a study conducted in 2003 (Cocozella et al.
2003), and 30 % in 2006 (Sheehan et al. 2012) (prevalence
of ever-having injected drugs in both samples was 43 %).
A 2011 study from Brazil also showed a current/past HCV
infection rate of 32 % (Oliveira-Filho et al. 2013). In DU
among mental health patients, no difference in prevalence
was seen for DU compared to other studies (Carmo et al.
2013).
Data for anti-HCV among NIDU ranged from 0 to 10 %
with the highest values found in a recent study from Brazil
(8 %) (Germano et al. 2010), and Uruguay (10 % in 2003)
(Osimani and Latorre 2003). The pooled value was 3.6 %
(CI 95 % 2.6–4.5 %), PI (2.34, 7.58).
HCV infection rate for IDU varied considerably between
and within countries (Brazil, Puerto Rico). The highest val-
ues were found in Argentina (55 % in 2001) (Weissenbacher
et al. 2003), Brazil (53 % in 1998, 46 % in 2001) (Caiaffa
et al. 2006), Puerto Rico (89 % in 2006) (Reyes et al. 2006)
and Mexico (Ciudad Juarez and Tijuana) (96 % in 2005)
(Frost et al. 2006). A study from Colombia (Bogota) found
the lowest anti-HCV prevalence (1.7 %) in IDU (Mejia and
Perez 2004). The latter is in agreement with another study
conducted in another part of Columbia that indicated an
absence of anti-HCV in DU and also in prison inmates who
were drug users (Bautista Amorocho et al. 2011). Pooled
regional anti-HCV prevalence among IDU was 49 % (CI
95 % 22.6–76.3 %) with significant heterogeneity among
studies (p\ 0.01), PI (33.45, 62.76).
Four studies investigated both anti-HCV and HCV-RNA
infection rate in DU, with six data points in total (Cocoz-
ella et al. 2003; Novais et al. 2009; Oliveira-Filho et al.
2013; Monsalve-Castillo et al. 2007) (Fig. 3). In all but one
study (Oliveira-Filho et al. 2013), prevalence was much
lower for HCV-RNA. HCV-RNA prevalence was much
higher in IDU than in DU and NIDU in the study by Oli-
viera-Filho et al. who investigated all three populations.
Only three studies from Brazil (Lopes et al. 2009; Novais
et al. 2009; Oliveira-Filho et al. 2013) determined HCV
genotypes. The study from Para´ found a high prevalence of
genotype 1b (42 %), especially in NIDU (50 %), while in
the other two studies, individuals had genotype 1a in over
60 %.
Comparison of results among population groups
For HCV current/past infection, IDU presented the highest
prevalence (Fig. 2). The study from Mejia and Perez was
the only to report a prevalence below 10 %. Among DU,
NIDU belonged to the less at risk populations, similar to
those found among MSM (with values below 10 %, range
0–10 %). SW, MSM and NIDU summary regional esti-
mates for HCV current or past infection are 2, 3 and 3.6 %,
respectively. Prison inmates presented higher values, with
a regional value of 12.5 %, with prevalence rates declining
over the years.
Information on HCV current infection prevalence was
only available in two of the five groups of interest (Fig. 3).
In general, it was lower than anti-HCV infection rates,
ranging from 1 to 46 %. It was below 10 % in all studies on
prison inmates.
Discussion
To the best of our knowledge, this is the first review that
systematically summarizes data on hepatitis C prevalence in
five key populations from LAC. More than 50 % of studies
investigated drug users. There was a significant lack of
studies for male sex workers and the transgender population.
Nearly 50 % of all publications included were from Brazil.
There are no data for many countries in the region, and
studies from only ten countries were included overall.
Whereby, the need for greater investment in HCV surveil-
lance studies is high. As reported by the World Health
Organization’s Global policy report on the prevention and
control of viral hepatitis (WHO 2013a, b), more than 70 % of
WHO member countries in LAC indicated that WHO assis-
tance would be necessary for ‘‘viral hepatitis surveillance’’
and ‘‘estimating the national burden of viral hepatitis’’.
As shown by this review, HCV prevalence results agree
with the common epidemiological knowledge on HCV
transmission routes. When analyzing HCV prevalence
among MSM in the region (pooled 3 % anti-HCV preva-
lence), we must consider that there can be overlapping
injecting drug use and HIV co-infection. Prevalence values
appear in consonance with Buffington et al. who report
1.5–3.6 % HCV prevalence among non-injecting and
injecting MSM, respectively, in several USA cities (Buff-
ington et al. 2007) or 2.1 % HCV prevalence among MSM
clinic attendees in England (Ward and Lee 2014). Results
suggest that this population presents a higher risk of HCV
than the general population highlighting the need for a
greater focus on surveillance and services for MSM
(Tohme and Holmberg 2010; Ponde 2011). The rate of
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infection due to sexual transmission is believed to be low,
but factors such as unprotected sex with multiple sex
partners, traumatic sex, co-infection with HIV or other
STIs increase the risk of transmission and chronicity once
infected with HCV (Terrault et al. 2013).
This review focused on vulnerable and risk groups that
can have overlapping risk behaviors for HCV transmission.
The authors recognize the limitations as information on
overlapping risk behaviors in most cases was not readily
available for this review.
This study updates and adds-on to reviews on HCV
among injecting drug users worldwide (Aceijas and Rhodes
2007; Nelson et al. 2011). Our findings confirm Aceijas and
Rhodes review that indicated important variation of HCV
prevalence among IDUs in the region. The findings are also
consistent with global figures. Nelson et al. found, globally,
HCV prevalence among IDUS between 60 and 80 % in 26
countries, and in USA, Russia and China, countries with
the largest amount of IDUs, HCV prevalence is estimated
from 67 to 73 %. HCV prevalence among FSW was among
the lowest found in some countries, and varying prevalence
most likely reflects varying levels of injecting drug use.
Findings among sex workers are consistent with studies in
other regions (Chen et al. 2015; Praseeda et al. 2013;
Rantala and van de Laar 2008). For prison inmates, the
pooled estimates concur with the regional estimates pro-
vided by Larney et al. (2013) and are lower than those in
Asia, Europe and North America.
With regard to the diagnosis of HCV infection, all
studies used anti-HCV positivity as serological marker that
does not distinguish between current and past HCV
infection. Only a few publications evaluated HCV-RNA,
and even fewer evaluated genotypes of HCV infection.
This is likely related to the fact that testing for HCV-RNA
and genotyping is technically more complicated and costly.
Nevertheless, burden of disease for current HCV infection
measured by HCV-RNA and genotyping is of great interest
from an epidemiological as well as treatment response
perspective.
All publications that evaluated genotypes were studies
in Brazilian drug users. Data suggest that genotype 1a
might not always be the predominant type (Oliveira-Filho
et al. 2013). Further investigation in other countries and
key populations are needed to support policies for thera-
peutic schemes.
Among the limitations of the study are a low sample size
cutoff criteria (75 participants or greater) that were decided
upon given the paucity of studies in the region and different
sampling methodology that could bias prevalence results.
Thirteen percent of the fifty five studies were excluded
because of a small sample size, but results were not sig-
nificantly different in prevalence rates from those with
higher sample sizes. Another limitation is that the full data
extraction was conducted by only one reviewer with an
additional reviewer for only a sample of studies. While
there was full agreement between reviewers for the sample
reviewed by both, variations in data collection could occur
for the additional studies not reviewed by both. Other
limitation for providing pooled results is the high hetero-
geneity present among HCV prevalence in the studies. The
high heterogeneity in the different analysis can be
explained by differences in years of publication of the
studies, inherent differences between risk groups and
geographic locations. This high heterogeneity may limit
the value of the regional summary measures presented;
however, differences among prevalence values were
expected and could be ascribed to true differences in the
prevalence of infection among risk groups and geographi-
cal areas. Results can also be affected due to overlapping
HIV/HCV epidemics, mainly in IDU and prison inmates. It
Fig. 3 Forest plot for current Hepatitis C infection prevalence Hepatitis C infection in Latin America and the Caribbean from 2000 to 2013. DU
drug users, IDU injecting drug users, NIDU non-injecting drug users
Hepatitis C in key populations in Latin America… 795
123
is important to consider that HIV infection is significant in
the same population groups studied for HCV and co-in-
fection results in a more rapid progression of liver disease
and HCV-related liver disease is a major cause of death for
people living with HIV. Prevalence figures of HCV can be
affected because the likelihood of chronic infection of
HCV is higher for people living with HIV, while, on the
other hand, mortality may be higher among persons co-
infected by HCV and HIV.
This systematic review and meta-analysis summarized
and assessed trends in prevalence of hepatitis C infection in
high risk populations of the region using conventional
methods for combining study data. Thus, the Forrest plots
presented do not compare risk ratios or other comparative
summary measures but prevalence of Hepatitis C. The
search strategy included different databases such as
Pubmed and Lilacs which is a specific source of scientific
articles in the region; we did not include the EMBASE
database due to lack of access to such database.
In conclusion, these findings emphasize the need to
strengthen surveillance of hepatitis C prevalence targeted
towards key populations in LAC using a broader frame-
work of risk and vulnerability. Based on these findings,
prevention and treatment strategies should include and
focus on most-at-risk and vulnerable populations to
respond to the epidemic of hepatitis C infection.
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